The US Food and Drug Administration (FDA) has approved a generic drug developed by Taiwan-based TTY Biopharm Co Ltd (台灣東洋藥品) to treat acute promyelocytic leukemia (APL), the company said on Sunday.
The drug, arsenic trioxide, sold under the brand name Asadin, was first approved for medical use in the US last year, and is listed by the WHO as an essential medicine for treating APL.
APL, a rare form of acute myeloid leukemia (AML), is distinguished by there being too many immature blood-forming cells in the blood and bone marrow, which leads to a shortage of normal white and red blood cells in the body.
Photo: Chang Chia-ming, Taipei Times
It needs to be treated differently from other types of AML, and arsenic trioxide combined with all-trans retinoic acid has become the standard treatment for the cancer.
When APL was first identified in 1957, APL patients had a median survival rate of less than a week, but now 10-year survival rates are plausible thanks to improvements in diagnosis and medication.
TTY Biopharm said in a statement that it hoped the approval of its generic drug could help patients in the US.
The company first received a license to make the drug from the Taiwanese FDA in 2002. It was the first APL treatment license issued in Taiwan.
From 2018, the company developed the drug further under a milestone payment contract with another partner, which it did not identify.
The partner is responsible for the sale, licensing and approval of the TTY Biopharm’s generic drug in international markets, such as Malaysia, the Philippines, Thailand, the US and Vietnam.
The US FDA approval was the first received by TTY Biopharm for any of its drugs, and recognizes the company’s research and development capabilities and manufacturing strength, the company said.
As the materials used to make the drug are highly toxic, the company has partnered with National Central University to create a recycling technique for arsenic ions that makes wastewater from the drug production process safe to release.
In related news, TTY Biopharm’s board of directors yesterday approved the dismissal of general manager Shih Chun-liang (施俊良), after Shih admitted to being involved in an insider-trading scandal involving the company’s shares.
TTY Biopharm chairman Lin Chuan (林全) is also to act as general manager, the company said in a regulatory filing.
Additional reporting by Kao Shih-ching
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue jumped 48 percent last month, underscoring how electronics firms scrambled to acquire essential components before global tariffs took effect. The main chipmaker for Apple Inc and Nvidia Corp reported monthly sales of NT$349.6 billion (US$11.6 billion). That compares with the average analysts’ estimate for a 38 percent rise in second-quarter revenue. US President Donald Trump’s trade war is prompting economists to retool GDP forecasts worldwide, casting doubt over the outlook for everything from iPhone demand to computing and datacenter construction. However, TSMC — a barometer for global tech spending given its central role in the
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
PRESSURE EXPECTED: The appreciation of the NT dollar reflected expectations that Washington would press Taiwan to boost its currency against the US dollar, dealers said Taiwan’s export-oriented semiconductor and auto part manufacturers are expecting their margins to be affected by large foreign exchange losses as the New Taiwan dollar continued to appreciate sharply against the US dollar yesterday. Among major semiconductor manufacturers, ASE Technology Holding Co (日月光), the world’s largest integrated circuit (IC) packaging and testing services provider, said that whenever the NT dollar rises NT$1 against the greenback, its gross margin is cut by about 1.5 percent. The NT dollar traded as strong as NT$29.59 per US dollar before trimming gains to close NT$0.919, or 2.96 percent, higher at NT$30.145 yesterday in Taipei trading
RSS